

A study proves the connection between inflammatory markers and the increase of frailty in prostate cancer patients



Cristina Buigues, Omarc Cauli, Rut Navarro.

Fuente: Universitat de València noticias.

Experts from the Universitat de València and the Valencian Institute of Oncology (IVO) have proved how some inflammatory markers measured in the blood are related to the progression of the frailty syndrome in prostate cancer patients, the most common tumour in men.

The results of the study showed that the blood concentration of the inflammatory marker IL-6 concentration in blood and the count of lymphocytes (a kind of cells of the immune system that fight against infections, among other functions) are possible useful biomarkers for identifying weak patients and predict progression of frailty in prostate cancer patients under ADT treatment. Thus, this study suggests that these biomarkers should be used to guide clinical decisions about prostate cancer treatment based on a multidisciplinary approach including different health professionals.

The results of the study have been published in two renowned international journals in the field of Oncology and Urology.

More information: https://webediccion.uv.es/uvweb/uv-noticies/es/noticias/estudio-demuestra-relacion-marcadores-inflamatorios-progresion-fragilidad-pacientes-cancer-prostata-1285973304159/Novetat.html?id=1286152449434&plantilla=UV_Noticies/Page/TPGDetailNews